欧洲泌尿外科学会更新指南:肾细胞癌辅助治疗
欧洲泌尿外科学会肾细胞癌指南小组根据两项随机对照3期试验(包括S-TRAC)结果,评估了高危非转移性肾细胞癌术后1年舒尼替尼辅助治疗。因研究结果矛盾,小组结合证据质量、获益风险比、患者偏好和成本投票达成共识:不推荐高危肾细胞癌术后使用舒尼替尼辅助治疗。
要点
- 不推荐高危肾细胞癌术后患者使用舒尼替尼辅助治疗。
- 一项研究显示1年舒尼替尼使复发前时间延长1.2年,但另一项研究未显示获益。
- 尚未证明患者总生存延长,且许多高危患者未复发而舒尼替尼副作用大。
核心结论
- 指南小组投票达成共识:不推荐高危肾细胞癌术后患者使用舒尼替尼辅助治疗。
研究设计与样本
- 欧洲泌尿外科学会肾细胞癌指南小组基于两项随机对照3期试验(包括S-TRAC)更新推荐,小组包括患者权益组织代表。
主要发现
- 一项研究显示1年舒尼替尼治疗使疾病复发前时间延长1.2年,另一项研究未显示获益。
- 尚未证明患者总生存延长。
- 许多高危患者术后仍未复发,且舒尼替尼副作用大。
关键数值与推荐
- 不推荐高危肾细胞癌术后使用舒尼替尼辅助治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The European Association of Urology Renal Cell Carcinoma (RCC) guidelines panel updated their recommendation on adjuvant therapy in unfavourable, clinically nonmetastatic RCC following the recently reported results of a second randomised controlled phase 3 trial comparing 1-yr sunitinib to placebo for high-risk RCC after nephrectomy (S-TRAC). On the basis of conflicting results from the two available studies, the panel rated the quality of the evidence, the harm-to-benefit ratio, patient preferences, and costs. Finally, the panel, including representatives from a patient advocate group (International Kidney Cancer Coalition) voted and reached a consensus to not recommend adjuvant therapy with sunitinib for patients with high-risk RCC after nephrectomy. PATIENT SUMMARY: In two studies, sunitinib was given for 1 yr and compared to no active treatment (placebo) in patients who had their kidney tumour removed and who had a high risk of cancer coming back after surgery. Although one study demonstrated that 1 yr of sunitinib therapy resulted in a 1.2-yr longer time before the disease recurred, the other study did not show a benefit and it has not been shown that patients live longer. Despite having been diagnosed with high-risk disease, many patients remain without recurrence, and the side effects of sunitinib are high. Therefore, the panel members, including patient representatives, do not recommend sunitinib after tumour removal in these patients.
引用
- Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. Eur Urol. 2016. PMID: 27986369. doi:10.1016/j.eururo.2016.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。